Ac2-26 peptide

Ac2-26 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

Ac-AMVSEFLKQAWFIENEEQEYVQTVK-OH

Ac-Ala-Met-Val-Ser-Glu-Phe-Leu-Lys-Gln-Ala-Trp-Phe-Ile-Glu-Asn-Glu-Glu-Gln-Glu-Tyr-Val-Gln-Thr-Val-Lys-OH

25

95.95%

C₁₄₁H₂₁₀N₃₂O₄₄S

3089.41

Synthetic

Powder

Ac2-26 is the N terminal fragment of annexin A1 and an annexin/lipocortin 1 mimetic. Ac2-26 can inhibit leukocyte extravasation, reduce neutrophil adhesion and emigration, promote detachment of neutrophils from activated mesenteric endothelium and accelerate epithelial wound repair. Local intestinal delivery of Ac2-26 encapsulated within targeted polymeric nanoparticles accelerates healing of murine colonic wounds after biopsy-induced injury.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Perretti and Gavins (2003) Annexin 1: an endogenous anti-inflammatory protein. News Physiol.Sci. 18 60 PMID: 12644621
• Leoni et al (2015) Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J.Clin.Invest. 125 1215 PMID: 25664854
• Possebon et al (2018) Mimetic peptide AC2-26 of annexin A1 as a potential therapeutic agent to treat COPD, International Immunopharmacology, 63 270 PMID: 30121452

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.